Laura Williams
Chief Tech/Sci/R&D Officer at ARDELYX, INC.
Net worth: 3 M $ as of 2024-03-30
Profile
Laura A.
Williams is currently the Chief Medical Officer at Ardelyx, Inc. She previously worked as an Independent Director at Imara, Inc. Laura also held the position of Vice President-Clinical Development at Myovant Sciences, Inc. from 2016 to 2017, and as Senior Vice President-Clinical Development at AMAG Pharmaceuticals, Inc. from 2017 to 2020.
She has a graduate degree from the University of Washington, an undergraduate degree from Mississippi State University, and a doctorate degree from the University of Iowa.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARDELYX, INC.
0.16% | 2024-02-19 | 380,138 ( 0.16% ) | 3 M $ | 2024-03-30 |
Laura Williams active positions
| Companies | Position | Start |
|---|---|---|
| ARDELYX, INC. | Chief Tech/Sci/R&D Officer | 2020-12-31 |
Former positions of Laura Williams
| Companies | Position | End |
|---|---|---|
| AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-12-31 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 2017-07-31 |
| IMARA | Director/Board Member | - |
Training of Laura Williams
| University of Washington | Graduate Degree |
| Mississippi State University | Undergraduate Degree |
| University of Iowa | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARDELYX, INC. | Health Technology |
| Private companies | 3 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Laura Williams
